7.72
0.32 (4.32%)
| Previous Close | 7.40 |
| Open | 7.16 |
| Volume | 18,855 |
| Avg. Volume (3M) | 36,267 |
| Market Cap | 28,195,600 |
| Price / Sales | 3.36 |
| Price / Book | 2.94 |
| 52 Weeks Range | |
| Earnings Date | 26 Mar 2025 - 31 Mar 2025 |
| Profit Margin | -122.46% |
| Operating Margin (TTM) | -65,066.67% |
| Diluted EPS (TTM) | -2.62 |
| Quarterly Revenue Growth (YOY) | -99.90% |
| Total Debt/Equity (MRQ) | 0.18% |
| Current Ratio (MRQ) | 10.68 |
| Operating Cash Flow (TTM) | -10.72 M |
| Levered Free Cash Flow (TTM) | -5.20 M |
| Return on Assets (TTM) | -20.34% |
| Return on Equity (TTM) | -70.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Pulmatrix, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -1.67 |
|
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.65% |
| % Held by Institutions | 9.01% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Highline Wealth Partners Llc | 30 Sep 2024 | 0 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 21 Mar 2025 | Announcement | Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets |
| 22 Jan 2025 | Announcement | Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |